Knop, S
Langer, C
Engelhardt, M
Mügge, L-O
Reichle, A
Rösler, W
Bassermann, F
Hertenstein, B
Kunitz, A
Röllig, C
Ostermann, H
Schäfer-Eckart, K
Ringhoffer, M
Günther, A
Junghanss, C
Biersack, H
Schreder, M
Liebert, A
Held, S
Einsele, H
Bargou, R C
,
Article History
First Online: 25 April 2017
Competing interests
: Stock ownership: WR, Amgen, Immunomedics. Honoraria: SK, Celgene Germany, Amgen Germany, BMS Germany, ONYX Inc., Janssen Germany; ME, Celgene, Janssen, MSD, Amgen; L-OM, Celgene, Janssen-Cilag, Novartis; FB, Celgene; MR, Celgene; AG, Novartis, Celgene, Janssen; MS, Novartis; HE, Janssen, Amgen, Novartis, Celgene; RCB, Amgen, Novartis, GeoMab. Consultant or advisory role: SK, Celgene Germany, Amgen Germany, Celgene Inc.; CL, Celgene, Janssen, Amgen, Novartis, Takeda, BMS; <i>ME</i>, Celgene, Janssen, MSD, Amgen; WR, Janssen, MSD; FB, Celgene; BH, Amgen; CR, Amgen, BMS, Celgene, Janssen, Roche, Takeda; HO, MSD, Gilead, AstraZeneca, Teva; <i>AG</i>, Novartis, Takeda; HB, BMS, Roche, Pfizer, MSD, Sanofi; HE, Janssen, Celgene, Amgen; RCB, Amgen, Novartis, GeoMab. Speakers’ bureau: CR, Amgen, BMS, Celgene, Janssen, Roche, Takeda; HO, MSD, AstraZeneca, Novartis, Teva; HE, Janssen, Celgene, Novartis. Research funding: L-OM, Celgene; FB, Celgene; CR, Bayer; HO, MSD, Genzyme, Cereus; HE, Amgen, Celgene, Janssen. Patents, royalties, other intellectual property: RCB, Amgen. Travel, accommodation, expenses: CL, Celgene, Takeda, BMS; ME, Celgene, Janssen, MSD, Amgen; L-OM, Novartis, Celgene; WR, medac, Janssen, MSD; <i>FB</i>, Celgene, BMS; <i>BH</i>, Teva, Amgen, Novartis, Neovi; CR, Amgen, Celgene, Janssen, Gilead; HO, MSD, Gilead, AstraZeneca; MR, medac; HB, Jazz, Eusapharma, Sanofi, Amgen; MS, Celgene; RCB, Amgen, Novartis, GeoMab. The remaining authors declare no conflict of interest.